Immunome, Inc. (IMNM) Deep Dive Video

Name: Immunome, Inc. (IMNM) Deep Dive Video | Flash
Uploaded: 2025-12-19T17:42:32.271
Description: A de-risked Phase 3 “best-in-class” desmoid asset plus a Siegall-built ADC/RLT expansion—IMNM’s upside is now about label and launch execution, not clinical proof.

Summary

A de-risked Phase 3 “best-in-class” desmoid asset plus a Siegall-built ADC/RLT expansion—IMNM’s upside is now about label and launch execution, not clinical proof.

View IMNM stock page · Read the IMNM research report

Loading the video player…